According to a report by Intel Market Research, the global Liraglutide API Market was valued at USD 215 million in 2025, estimated at USD 230 million in 2026, and projected to reach USD 425 million by 2034, representing an 8.0% CAGR during 2026–2034. The market covers pharmaceutical-grade liraglutide active ingredient supplied for regulated finished-dose manufacturing, excluding finished injectable products, devices, excipients, fill-finish, packaging and retail margins. Demand spans type 2 diabetes and weight management, while generic approvals are broadening the customer base beyond the originator supply network.

Explore the full report: Liraglutide API Market Report

Why Is Demand Increasing?

• Generic market entry: FDA approved Hikma’s first generic liraglutide referencing Victoza in December 2024 and Teva’s first generic referencing Saxenda in August 2025, creating additional regulated demand for qualified API suppliers.

• Large diabetes population: The report cites 589 million adults aged 20–79 living with diabetes worldwide in 2024, providing a substantial treatment base for liraglutide and other GLP-1 therapies.

• Essential-medicine relevance: The 2025 WHO Model List of Essential Medicines added the GLP-1 class for selected adults with type 2 diabetes and listed liraglutide as a therapeutic alternative to semaglutide, strengthening its access relevance.

Pharmaceutical Biologics & GLP-1 Industry Watch

The liraglutide API industry is transitioning from an originator-led model toward a mixed originator-and-generic supply structure. Generic launches are increasing the importance of merchant peptide API suppliers capable of validated commercial-scale synthesis, purification, impurity control and regulatory documentation. The report also highlights the changing competitive environment created by once-weekly incretin therapies, which has reduced branded Victoza momentum while creating greater emphasis on affordability and generic access. Specialist peptide manufacturers including Bachem, PolyPeptide and CordenPharma are expanding broader peptide manufacturing capabilities, although the report does not establish that every such company supplies commercial liraglutide. Regulatory scrutiny of peptide quality and controlled manufacturing is also increasing the importance of GMP systems and traceable supply chains.

Segmentation Highlights

• By Supply Model: Captive/In-house Manufacturing and Merchant/Third-Party API Supply. Captive production remains the largest value segment, while merchant supply is expected to grow faster as generic manufacturers enter regulated markets.

• By Application: Type 2 Diabetes, Weight Management/Obesity and Other Approved or Development Uses. Type 2 diabetes remains the largest established application, while weight management represents an important access-led opportunity.

• By Region: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

• Selected Countries: United States, Canada, Germany, United Kingdom, France, China, Japan, India, Brazil, GCC countries and South Africa.

Regional Outlook

• North America: The largest regional market by value in 2025, supported by established GLP-1 use, high diabetes-treatment expenditure and active U.S. generic approvals.

• Europe: A mature market with established liraglutide use and an expanding generic pathway. EMA granted Liraglutide STADA marketing authorization valid across the EU in July 2026.

• Asia-Pacific: A strategically important region because of its large diabetes population and pharmaceutical manufacturing depth. The report cites 89.8 million adults aged 20–79 with diabetes in India in 2024.

• Latin America: Lower-cost generic liraglutide can support longer-term volume expansion as diabetes prevalence rises and payers seek more affordable treatment options.

• Middle East & Africa: High diabetes prevalence and substantial treatment-access gaps create an opportunity for lower-priced products, subject to reimbursement, supply and cold-chain infrastructure.

Download the free sample report: Free Sample Report

Why This Market Matters

Liraglutide remains commercially relevant across two established applications: type 2 diabetes and chronic weight management. The market is nevertheless undergoing an important transition as newer once-weekly incretin therapies influence branded demand while generic approvals create additional finished-dose customers. Novo Nordisk reported DKK 3.02 billion in Victoza sales in 2025, down 45% in Danish kroner from the prior year, according to the report.

For API suppliers, the opportunity is increasingly tied to qualified external supply rather than premium branded expansion. Liraglutide is a complex peptide requiring controlled synthesis, purification, impurity characterization and GMP release testing. These requirements make commercial-scale manufacturing capability, regulatory documentation, quality consistency and predictable lead times important elements of supplier qualification.

Competitive Landscape

• Novo Nordisk A/S — Developed liraglutide and retains an integrated position across API, finished-dose manufacturing and commercialization.

• Hikma Pharmaceuticals PLC — Entered the U.S. generic liraglutide pathway with its December 2024 approval referencing Victoza.

• Teva Pharmaceutical Industries Ltd. — Entered the U.S. generic weight-management pathway with its August 2025 approval referencing Saxenda.

• STADA Arzneimittel AG — Received EU marketing authorization for Liraglutide STADA in July 2026, expanding regulated generic participation.

• Bachem Holding AG — Included among specialist peptide manufacturers expanding broader industrial peptide capabilities relevant to the external peptide manufacturing ecosystem.

The report identifies competition around regulatory-grade quality, process yield, capacity security, cost efficiency and the ability to support generic customers across multiple jurisdictions.

View the full report: Liraglutide API Market Report

Frequently Asked Questions

What is the size of the Liraglutide API Market?
The market was valued at USD 215 million in 2025, estimated at USD 230 million in 2026, and is projected to reach USD 425 million by 2034 at an 8.0% CAGR during 2026–2034.

Which region leads the Liraglutide API Market?
North America leads in value, supported by high diabetes-treatment expenditure, established GLP-1 use and active U.S. generic approvals.

What is driving growth in the Liraglutide API Market?
Genericization is a central near-term catalyst, while WHO essential-medicine inclusion and broader access to lower-cost products support demand. Competition from newer once-weekly incretins and finished-dose price erosion remain important market constraints.

What Does the Full Report Cover?

The full Intel Market Research study provides market sizing from 2025 through 2034, including the 2026 estimate, 2034 forecast and 8.0% CAGR. It analyzes supply models covering captive/in-house and merchant/third-party API production, applications across type 2 diabetes and weight management, and five regional markets with selected country signals. The report examines generic approvals, peptide synthesis and purification, impurity control, regulatory documentation, GMP requirements, procurement dynamics and external manufacturing capacity. It also evaluates the impact of newer incretin therapies, price erosion, essential-medicine policy, access expansion, cold-chain requirements and regulatory controls on peptide ingredients. Competitive coverage includes the originator, generic manufacturers and specialist peptide companies.

About Intel Market Research

Intel Market Research provides strategic market intelligence and industry analysis across biotechnology, pharmaceuticals, healthcare infrastructure and specialized markets. Its research covers market sizing, segmentation, competitive analysis, regional assessment, regulatory developments and industry forecasts.

Contact Details

Website: www.intelmarketresearch.com
Asia-Pacific: +91 9169164321